A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Alvelestat (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ATALANTa
- 08 Apr 2019 Status changed from not yet recruiting to recruiting.
- 15 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 17 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.